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follicle count (AFC), and ovarian volume.[2,3] These have 
been summarized in Table 1.
AFC is considered as a gold standard for measurement 
of OR and is considered necessary before planning 
assisted reproduction support.[4] It is suggested 
that an optimum response to infertility assistance is 
reflected as a retrieval of at least 5 oocytes on ovarian 
stimulation.[5] Furthermore, an exaggerated AFC (>19) 
is linked to potential complications such as ovarian 
hyper stimulation syndrome (OHSS),[3] rendering 
its evaluation as a better tool for optimization 
of protocol that may reduce the chances of cycle 
cancellation. However, it has its own drawbacks 
such as prerequisite of a skilled operator and latest 
machinery that reliably assess the count.[6] In addition, 
its inability to reveal the quality of healthy oocytes 
INTRODUCTION
Assessment of the status of an ovarian function is 
essential to evaluate and plan infertility interventions. 
In recent times, estimation of ovarian reserve (OR) is 
the most commonly used criteria to reflect the quality 
and quantity of oocytes, in turn imitating the fertility 
potential of a female.[1] With advancing age, a drop in 
the extent of OR proportionately reflects decline in a 
female’s reproductive capabilities. Hence, its estimation 
provides an approximation of fertile years left for a 
woman. Several markers are used to reflect OR in 
infertility clinics that include patient’s age, serum follicle 
stimulating hormone (FSH), luteinizing hormone (LH), 
anti‑Mullerian hormone (AMH), estradiol levels, antral 
Background: This study aimed to evaluate the strength of anti‑Mullerian hormone (AMH) and follicle stimulating hormone (FSH) 
in reflecting the antral follicle count (AFC) in infertile females. Materials and Methods: This cross‑sectional study was conducted 
on 160 females, visiting infertility clinic for assisted reproduction. Serum samples collected on the 3rd day of the cycle were assayed 
for FSH, luteinizing hormone, and AMH while AFC was assessed via transvaginal ultrasound. The study cohort was segregated into 
three groups based on AFC. Results: Chronological age and FSH was significantly high in females with very low AFC (P < 0.01 and 
0.009, respectively), yet they failed to discriminate patients with normal and higher follicle count (P = 0.65 and 0.84). Conversely, 
AMH reported highly significant difference between very low AFC and with those having either normal AFC (P = 0.002) or higher 
AFC  (P  =  0.001). Moreover, a significant difference in AMH was observed between normal and higher AFC group  (P  =  0.04). 
Conclusion: Compared to female’s age and FSH, AMH is superior in clustering study cohort on the bases of antral follicular pool, 
especially in setups with nonavailability of technological expertise to assess AFC. Incorporation of AMH along with other biomarkers 
improves estimation of baseline ovarian reserve, required to standardize dose for optimum response; avoiding the risk of failure to 
retrieve oocyte or inappropriate stimulation leading to ovarian hyperstimulation syndrome. Further prospective studies are required 
to ascertain its role in predicting the outcomes of ART in such patients.
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results in counting even those follicles that may not act 
in response to treatment.[7]
At present, in setups that lack ultrasonography facilities 
for the assessment of AFC, serum FSH is widely used 
along with patient’s age; based on these markers, patients 
are either advised to farther wait for natural conception 
or offered infertility treatment. Various studies imply 
chronological age as a weak predictor of fertility as even 
young patients at the times report reduced OR.[8] In regards 
to FSH, it shows high degree of variability as factors such 
as exogenous administration of FSH in the form of oral 
contraceptive pills (OCP) can alter the results obtained.[9] 
Nowadays, AMH is being preferred over other indicators 
as its levels are independent of menstrual cycle phases and 
is fairly easier to estimate through blood sampling.[9]
In this study, we aimed to compare the true accuracy of 
AMH and FSH in correlating with the number of AFC 
in infertile population. For this purpose, we divided the 
cohort into three subgroups based on AFC count; those 
with <5 follicles (Group A), between 5 and 19 (Group B), 
and greater than 19 follicles (Group C). We evaluated the 
strength of AMH and FSH in characterizing the population 
into sub‑groups and witnessed AMH as a superior predictor 
in distinguishing among them.
MATERIALS AND METHODS
This cross‑sectional study was conducted by means 
of the data collected from 160 infertile females, aged 
20–43 years who visited Australian Concept Infertility 
Medical Center (ACIMC) during June 2014 to March 2015. 
Institutional review board of ACIMC granted the exception 
of Ethical Review consent as this retrospective study could 
not affect the clinical decision made for infertility treatment. 
The anonymity of the records was carried out in view of 
keeping patient confidentiality intact. Besides age, the 
inclusion criteria also required that participants had intact 
female reproductive organs and no history of prior ovarian 
procedures or endocrine dysfunction. Women who had 
previously received ovarian stimulation treatment or OCP 
were excluded from the study.
The serum samples were obtained over days 3 of the 
menstrual cycle from all participants for baseline AMH, 
FSH, and LH measurements before the commencement 
of treatment. The hormonal assays were carried out on 
supernatant fluid maintained between 2 and 8°C. AFCs were 
assessed via transvaginal ultrasonography by utilization of 
an Aloka SSD‑1000 (Japan) with a 5 MHz probe, on menstrual 
cycle day 3. Follicular diameter of <10 mm was used as a 
cutoff while counting in both ovaries to determine the cohort 
with inter observer coefficient of variation (CV) <5%.
All samples were assayed employing the use of AMH Gen 
11 ELISA reagent kit (Beckman coulter, ref a79765) with 
an analytical sensitivity of 0.57 pmol/L. Intra‑assay CV 
was <5.4% while inter‑assay CV was 5.6%. Regarding FSH, 
samples were assayed utilizing the Elecys reagent kit with 
intra‑assay CV of <3% and inter‑assay CV of <6%.
RESULTS
In our study, the mean body mass index (BMI) of the 
participants was higher than the South Asia cutoff for 
obesity, i.e. 25 kg/m2. The mean serum AMH levels were 
recorded as 1.6 ± 1.37 ng/ml although the mean age was 
observed as 33.6 ± 6.03 year. The serum FSH levels, as well as 
AFC of the whole population, was recorded within normal 
range as listed in Table 2.
Subsequently, the participants were divided into three 
groups based on their evaluation of the number of 
antral follicles. Group A comprised individuals with 
AFC <5 follicles, Group B had a range from 5 to 19 follicles 
while Group C included participant with AFC >19 follicles. 
Table 3 presents the biophysical and biochemical variables 
of the cohort subgrouped according to the AFC criterion.
The post hoc analysis between AFC and parameters such as 
age, BMI, FSH, and AMH highlighted the significance of 
these markers in categorizing the three groups.
Age appeared to be a significant predictor for females 
having very low number of ovarian follicles (P < 0.01) but 
it failed to differentiate between those with normal or more 
than 19 follicles (P = 0.65) (Groups B and C).
Table 1: Ovarian reserve tests and markers adapted 
from Jirge, 2011
Tests Ovarian reserve marker
Biological Chronological age
Biochemical FSH
LH
FSH: LH ratio
Inhibin B
Estradiol
AMH
CCCT
GAST
EFORT
Biophysical AFC
Ovarian volume
Ovarian blood flow
Histological Ovarian biopsy
CCCT=Clomiphene citrate challenge test; GAST=Gonadotropin‑releasing hormone 
agonist stimulation test; EFORT=Exogenous FSH ovarian reserve test; FSH=Follicle 
stimulating hormone; LH=Luteinizing hormone; AMH=Anti Mullerian hormone; 
AFC=Antral follicle count
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The difference in FSH was found to be nonsignificant 
among patients in Groups A and B (P = 0.08) and between 
Groups B and C (P = 0.84). Moreover, it was merely able to 
significantly differentiate between patients with <5 follicles 
and those with more than 19 follicles (P = 0.009).
AMH was found to be the most comparable predictor to 
AFC in categorizing the population as there was a significant 
difference among all three groups. The P value was highly 
significant among patients with low AFC and normal 
AFC, i.e., Group A and B (P = 0.002) as well as between 
Groups A and C (P = 0.001). Furthermore, AMH levels were 
successful in highlighting the significant difference between 
Group B and C (P = 0.04).
Finally, we performed ordinal regression analysis adjusting 
for age and BMI to estimate the odds ratio for determining 
the effect of AMH and FSH on AFC variations. The odds 
for AMH were 0.14 (95% confidence interval [CI]: 0.03, 
0.65 (P < 0.01)), while the odds for FSH was 1.42 (95% CI: 
0.72, 2.79 [P = 0.73]). As compared to FSH, AMH gave a 
better prediction of variation in the AFC.
DISCUSSION
In human‑assisted reproduction, ovarian response to 
gonadotropin stimulation is variable, hence, difficult 
to predict.[10] The evaluation of antral follicles on the 
transvaginal scan is often used as a gold standard to assess 
OR, standardize the dose of treatment, and to predict the 
likelihood of conception with the help of intervention. In 
this study, we compared the effectiveness of FSH; widely 
used OR and recently emerged AMH in reflecting the count 
of antral follicles in infertile females.
In our study, the mean age of infertile patients was found 
to be approximately 33 years. As chronological age is used 
as a marker of OR since many years, we scrutinized its 
strength in reflecting the follicular pool. Expectedly, higher 
age correlated with patients whom AFC had drastically 
declined, suggesting deterioration in the ovarian pool as 
female ages. However, it failed to segregate between women 
with healthy counts of follicles or an overblown AFC that is 
critical to reduce undesired effects of treatment. Literature 
too recommends age as a week reflector of the reserve as 
it is widely reported to differ even among age‑matched 
population.[11] Even though age does influence the fecundity 
of a female but its utility as a marker of OR can only be 
substantiated while synergistically using it along other 
biochemical and biophysical markers.[12] Undoubtedly, 
baseline OR status has an extensive role in infertility 
management. Primarily, it is decisive in suggesting either 
to wait for natural conception or to proceed for assisted 
reproduction. Furthermore, it assists in the standardization 
of doses that may lead to satisfactory response, avoiding the 
risk of inadequate reaction resulting in failure to retrieve 
a decent number of oocytes. In extreme cases, OR might 
predict the chances of inappropriate ovarian stimulation 
leading to potentially fatal complication termed as OHSS.[13] 
Thus, finest prediction of the ovarian pool is essential for 
grander results of ART. To this end, in secondary care 
hospital where technical expertise is not available to assess 
AFC, serum FSH is commonly used as an OR markers other 
than age, LH, inhibin, and ovarian volume.[6]
Regarding mean AFC of our study group, we reported 
approximately nine follicles per patient. However, while 
segregating the participants into three groups based of 
their AFC, 24% reported < 5 antral follicles which indicated 
determent in their ovarian pool. Likewise, 27.5% population 
was at the risk of hyperresponsiveness as they testified more 
than nineteen antral follicles on initial assessment. AFC is 
considered as the first test of choice in evaluating infertile 
patients as it reflects the baseline capability of ovarian 
pool to respond to treatment.[11] This promises for timely 
identification of women with shortened reproductive life 
span, requiring immediate intervention. Moreover, it leads 
to appropriate counseling of expected poor responders and 
in setting apart those females who may experience enhanced 
responsiveness.[13] Contrary to this, AFC evaluation has 
its own limitations. These include the requirement of 
latest equipment and skilled personnel, biasness due to 
Table 3: Biophysical and biochemical variables on the 
basis of antral follicle count cut‑off
Variables AFC (mean±SD)
<5 (n=38) 5–19 (n=78) >19 (n=44)
Age (year) 36.6±5.5* 33.2±6.5 32±4.6
BMI (kg/m2) 31.9±5.1 28.6±5.7 29.2±4.5
FSH (IU/L) 10.1±5.6* 8.5±5.1 7.25±3.4
LH (IU/L) 7.1±7.6 6.3±8.6 8.2±5.7
AMH (ng/ml) 0.5±0.6* 1.7±1.3* 2.2±1.7*
AFC 3.5±0.5 7.6±1.2 14.8±4.7
Data expressed as mean±SD. Mann–Whitney U‑test was used to compare the 
difference between groups. *P<0.05 considered significant. BMI=Body mass index; 
FSH=Follicular stimulating hormone; LH=Luteinizing hormone; AFC=Antral follicle 
count; AMH=Anti Mullerian hormone; SD=Standard deviation
Table 2: Descriptive statistics of the whole cohort
Variables Whole study population, n=160 (mean±SD)
Age (year) 33.6±6.03
BMI (kg/m2) 29.3±5.41
FSH (IU/L) 8.5±4.8
LH (IU/L) 6.9±1.06
AMH (ng/ml) 1.6±1.37
AFC 8.8±4.3
Infertility (year) 7.6±5.6
Data expressed as mean±SD. Mann–Whitney U‑test was used to compare the 
difference between groups. *P<0.05 considered significant. BMI=Body mass index; 
FSH=Follicular stimulating hormone; LH=Luteinizing hormone; AFC=Antral follicle 
count; AMH=Anti Mullerian hormone; SD=Standard deviation
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operator’s variability, incapability to visualize follicles in 
female with ovarian cysts or prior surgery, and counting 
both healthy and atretic follicles as capable to respond 
to treatment.[14] Therefore, we compared the strength of 
FSH; mostly commonly used OR in secondary care clinics 
and AMH; recently acclaimed as the best solo marker to 
reflect ovarian pool, in segregating infertile population. As 
blood test has a clear advantage of sample collection and 
avoidance of human error, these tests may be easily used in 
setups lacking the sophisticated technology to assess AFC.[14]
In this investigation, we found that serum FSH was 
incapable of significantly indicating sub‑groups with 
varied AFC. Although mean FSH levels in patients with 
very low AFC were higher (10.1 IU/L) than the other two 
sub‑groups as shown in Table 3, they were still within 
the normal range (<11 IU/L). This suggests that FSH may 
identify individuals only once considerable the loss of 
ovarian function has already occurred. Furthermore, the 
only significant difference reported in our study was among 
FSH levels of patients with <5 follicles and those with more 
than 19 follicles; however, it failed to segregate those with 
a high chance of life‑threatening OHSS. There have been 
discrepancies in the literature regarding the role of FSH as 
an accurate OR. Undoubtedly, it is the most widely used 
OR marker, but there is ample evidence to state that FSH 
levels begins to derange lately; thus, lone assessment of FSH 
or along with chronological age is losing their strength as 
timely and true indicators of OR.[15]
Interestingly, we found that serum AMH most accurately 
clustered the study cohort on the bases of antral follicular 
pool. The patients with low AFC had significantly lower 
mean AMH levels in comparison to normal as well as higher 
follicle count (P = 0.002 and 0.001, respectively). Perhaps the 
most striking finding in our investigation is that AMH was 
the only parameter that differentiated between the normal 
AFC and higher AFC group (P = 0.044). This raises the 
possibility of AMH’s clinical value in identifying patients 
with likelihood to develop hyperresponse to ovarian 
stimulation on the standard doses of gonadotropins.[16] 
Timely, identification of such patients would prevent the 
drastic complications of the unfortunate phenomenon 
OHSS. It may also have the potential to screen for polycystic 
ovarian syndrome as women with this condition are likely 
to have higher follicle counts, which is well correlated with 
AMH levels as our study has shown.[17] Our study strongly 
supports the addition of AMH assessment to evaluate 
woman before making decisions pertaining to infertility 
intervention.
As ethnic variation has been reported in the levels of 
AMH across the various population, this is the first study 
that compares the strength of FSH and AMH in reflecting 
the follicle count in Pakistani population. A collection 
of retrograde data is one of our study’s limitation; 
however, it provides ample evidence to support further 
studies highlighting the role of AMH as a robust OR 
marker. As ethnicity affects the ovarian pool as well as its 
responsiveness to ovarian stimulation, local studies are 
required to further strengthen the diagnostic role of AMH 
in reflecting a response to treatment in various ovarian 
dysfunctions.
CONCLUSION
AMH improves the estimation of baseline OR, required 
to predict optimum ovarian response during assisted 
reproduction. Compared to female age and FSH alone, 
AMH has a superior role in projecting accurate antral follicle 
pool, especially in setups where technological expertise to 
assess AFC is not available. Incorporation of AMH along 
with other biomarkers constitutes a better model for the 
prediction of ovarian response. Further prospective studies 
are required to ascertain its role in predicting the outcomes 
of ART in such patients.
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